Nuvation Bio Inc. (NUVB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Fintel reports that on December 11, 2025, HC Wainwright & Co. maintained coverage of Nuvation Bio (NYSE:NUVB) with a Buy ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial ...

Nuvation Bio stock is downgraded as price reflects Ibtrozi’s strong launch. Get insights on NUVB stock's forward revenue and investor strategies.

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic ...

In a report released today, Michael Yee from Jefferies assigned a Buy rating on Nuvation Bio (NUVB – Research Report), with a price target of $10.00. Michael Yee has given his Buy rating due to a ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief ...

Nuvation Bio enrolled the first patient in a late-stage study of Ibtrozi. The bigger story, though, was a Wall Street analyst's initiation of coverage on the stock. Shares of Nuvation Bio (NYSE: NUVB) ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic ...